Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPX4 | P36969 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.32 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19958480 | 0.89 | PDE4B (0.40) | GPX4PDE4BBTKKMT2AMEN1 | |
| SCHEMBL410338 | 0.80 | BTK (0.39) | GPX4PDE4BBTKALDH1A1CPN1 | |
| SCHEMBL20892965 | 0.80 | BTK (0.39) | GPX4PDE4BBTKALDH1A1CPN1 | |
| SCHEMBL18431410 | 0.80 | BTK (0.39) | GPX4PDE4BBTKALDH1A1CPN1 | |
| SCHEMBL26073819 | 0.79 | MEN1 (0.38) | GPX4BTKKMT2AMEN1ALDH1A1 | |
| SCHEMBL16907738 | 0.79 | ALDH1A1 (0.47) | GPX4PDE4BBTKKMT2ANPC1 | |
| SCHEMBL17481251 | 0.78 | BTK (0.38) | GPX4BTKKMT2AMEN1 | |
| SCHEMBL17616668 | 0.78 | BTK (0.40) | GPX4PDE4BBTKKMT2ANPC1 | |
| SCHEMBL19999883 | 0.78 | — | — | |
| SCHEMBL12840905 | 0.77 | GPX4 (0.40) | GPX4PDE4BBTKKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BEONE MEDICINES I GMBH (CH) | 2020-05-14 | — | — | US | disclosed |
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | CORVUS BIOPHARMACEUTICALS, LTD. (KY) | 2019-04-11 | — | — | US | disclosed |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | MERCK PATENT GMBH (DE) | 2018-06-21 | — | — | US | disclosed |
| EP-2970300-B1 | HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190106423-A1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ABL1, BTK, LYN | GPX4 3181/4885PDE4B 993/4885BTK 2/4885 |
| US-20180169094-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES AND THEIR USE AS IRAK INHIBITORS | IRAK2, IRAK3, IRAK1 | GPX4 4270/4885PDE4B 1239/4885BTK 16/4885 |
| US-20200148690-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS BRUTON'S TYROSINE KINASE MODULATORS | BTK, LCK, SYK | GPX4 3591/4885PDE4B 674/4885BTK 1/4885 |
| US-10870652-B2 | Compounds and methods for modulating bruton's tyrosine kinase | ABL1, BTK, LYN | GPX4 3181/4885PDE4B 993/4885BTK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.